# Clinical Outcomes of Hepatic Squamous Cell Carcinoma With Fibroblast Growth Factor Receptor 2 (FGFR2) Mutation: A Case Report

## TL;DR

A rare case of liver squamous cell carcinoma with an FGFR2 mutation is reported, highlighting the challenges in treating this aggressive disease.

## Contribution

This case report identifies FGFR2 alterations in a patient with primary squamous cell carcinoma of the liver.

## Key findings

- The patient had FGFR2 mutations and was diagnosed with primary squamous cell carcinoma of the liver.
- Treatment with gemcitabine-based therapies and erdafitinib failed to control disease progression.
- The patient's survival was 12 months, underscoring the poor prognosis of this rare cancer.

## Abstract

Primary squamous cell carcinoma of the liver (PSCCL) is an extremely rare disease with a poor prognosis. To date, few cancer-related genetic abnormalities in PSCCL have been reported. This report describes a case of PSCCL with FGFR2 alterations in a male patient in his 50s. The patient presented with loss of appetite and epigastric pain. Computed tomography confirmed an irregular mass in the liver and lymphadenopathy in the mediastinum and right supraclavicular region. Biopsies were obtained from the liver and right supraclavicular lymph nodes, and a diagnosis of squamous cell carcinoma was determined. No other primary lesions were identified, and PSCCL was diagnosed. Administration of gemcitabine + cisplatin and gemcitabine + S-1 was discontinued due to allergic reactions. Erdafitinib was then administered; however, the disease progressed. The patient passed away 12 months after the initial treatment. No established treatment options for PSCCL are currently available. Identifying cancer-related genetic abnormalities may help in making treatment decisions.